<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00818779</url>
  </required_header>
  <id_info>
    <org_study_id>Tekturna 1</org_study_id>
    <nct_id>NCT00818779</nct_id>
  </id_info>
  <brief_title>Direct Renin Inhibition Effects on Atherosclerotic Biomarkers</brief_title>
  <official_title>Effects of Direct Renin Inhibition on Atherosclerotic Biomarkers in Patients With Stable Coronary Heart Disease and Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Tech University Health Sciences Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Texas Tech University Health Sciences Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to assess if a new blood pressure medication, aliskiren, reduces
      various biomarkers of heart disease found in the blood in patients with a history of both
      heart disease and type 2 diabetes. The primary hypothesis is that aliskiren will reduce these
      biomarkers compared to a calcium channel blocker.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Agents that attenuate the renin angiotensin system (RAS), i.e. angiotensin converting enzyme
      inhibitors (ACE-Is) and angiotensin receptor blockers (ARB), have shown to have therapeutic
      benefit in a variety of cardiovascular disorders. ACE-Is are considered standard of care for
      secondary prevention of CAD by the AHA/ACC. Based on the HOPE study, the beneficial effects
      of ACE-Is in patients at high risk for cardiovascular outcomes may be beyond mere blood
      pressure control. In addition to their effects on blood pressure, aldosterone, and sodium and
      water absorption, blockade of the RAS with ACE-Is or ARBs alter key biomarkers of vascular
      inflammation, vascular endothelial function, and fibrinolytic balance. These surrogate
      biomarkers are thought to play a role in the progression of atherosclerosis. Biomarkers of
      vascular inflammation include vascular and intracellular cell adhesion molecule (VCAM and
      ICAM respectively) and c-reactive protein (CRP). Markers of endothelial function include
      endothelin-1 (ET-1) and the vasodilator nitric oxide (NO). Plasminogen activator inhibitor-1
      (PAI-1) is a prothrombotic marker associated with plaque proliferation and atherosclerosis
      progression.

      ACE-Is block the conversion of angiotensin 1 (Ang 1) to angiotensin 2 (Ang 2). &quot;ACE escape&quot;
      may attenuate the influence of ACE-Is despite proven benefits in clinical trials.

      Aliskiren is the first direct renin inhibitor approved by the FDA for the treatment of
      hypertension. It is a very specific and potent inhibitor of human renin. As such it may offer
      an advantage over ACE-I and ARB therapy as it blocks the rate limiting step of the RAS. It
      does not show a compensatory increase in RAS activity noted with ARBs or non-ACE production
      of Ang 2 as seen with ACE-Is. Aliskiren appears to have additive blood pressure lowering
      effects when added to ACE-I or ARB therapy.

      A very commonly prescribed antihypertensive, the dihydropyridine calcium channel blocker
      amlodipine, has a synergistic effect on lowering BP when used with an ACE-I. It has been
      shown to have mixed effects on atherosclerotic biomarkers in a variety of subjects. Type 2
      diabetes affects many of the atherosclerotic markers described above and as such can be a
      confounding variable in research involving these biomarkers.

      With the addition of a new therapeutic agent that affects the RAS, its different
      pharmacodynamic effects on the RAS compared to ACE-I and ARB therapy, and that Ang 2 levels
      are not fully blocked by ACE-I therapy, it is critical to better understand how the new class
      of direct renin inhibitors may influence atherosclerotic biomarkers in patients with a
      variety of cardiovascular disorders. The objectives of this application are to determine
      whether the direct renin inhibitor, aliskiren, affects atherosclerotic biomarkers in patients
      with stable coronary artery disease and diabetes currently receiving standard ACE-I therapy
      and if aliskiren has a more favorable effect on these markers compared to the calcium
      antagonist amlodipine.

      Large clinical trials have proven the benefit of RAS blockade in reducing cardiovascular
      morbidity and mortality. The significance of this research is that more information is needed
      to better understand how antihypertensive agents, particularly those that block the RAS,
      reduce cardiovascular disease beyond blood pressure reduction alone. Research that elucidates
      how agents may reduce atherosclerosis is very important to help better target drug therapy to
      a condition that is the leading cause of death in this country.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasminogen Activator Inhibitor 1</measure>
    <time_frame>6 weeks (change from baseline)</time_frame>
    <description>Plasminogen Activator Inhibitor 1 is a biomarker found in serum that indirectly assesses blood clotting activity. Lower PAI-1 levels are thought to be better than higher levels. The primary outcome is mean change from baseline and can include negative numbers as a result.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Level of Vascular Cell Adhesion Molecule</measure>
    <time_frame>6 week (change from baseline)</time_frame>
    <description>Surrogate biomarker cardiovascular risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Level of Intracellular Cell Adhesion Molecule</measure>
    <time_frame>6 week (change from baseline)</time_frame>
    <description>Surrogate biomarker of cardiovascular risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Level of C-reactive Protein</measure>
    <time_frame>6 week (change from baseline)</time_frame>
    <description>Surrogate biomarker of cardiovascular risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Level of Nitric Oxide</measure>
    <time_frame>6 week (change from baseline)</time_frame>
    <description>Surrogate biomarker of cardiovascular risk</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aliskiren 150-300 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5-10 mg amlodipine once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>150 - 300 mg once daily for 6 weeks</description>
    <arm_group_label>Aliskiren</arm_group_label>
    <other_name>Tekturna</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>5-10 mg once daily for 6 weeks</description>
    <arm_group_label>Amlodipine</arm_group_label>
    <other_name>Norvasc</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of type 2 diabetes

          -  Diagnosis of coronary artery disease

          -  Currently receiving therapy with an ACE-Inhibitor or Angiotensin Receptor Blocker

          -  Currently receiving antiplatelet therapy and statin therapy

          -  Baseline blood pressure &gt; 100/75 mm Hg

          -  BMI 25-35 kg/m2

        Exclusion Criteria:

          -  Concurrent calcium channel blocker therapy

          -  Documented peripheral edema

          -  Hyperkalemia

          -  Serum creatinine &gt; 2.0

          -  Diagnosed with proteinuria

          -  Diagnosed with liver dysfunction or serious rheumatological disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary E Meyerrrose, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Tech Health Sciences Center Department of Internal Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian K Irons, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Texas Tech University Health Sciences Center School of Pharmacy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2009</study_first_submitted>
  <study_first_submitted_qc>January 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2009</study_first_posted>
  <results_first_submitted>June 18, 2012</results_first_submitted>
  <results_first_submitted_qc>October 18, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 19, 2012</results_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>heart disease</keyword>
  <keyword>atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aliskiren</title>
          <description>Aliskiren 150-300 mg once daily</description>
        </group>
        <group group_id="P2">
          <title>Amlodipine</title>
          <description>5-10 mg amlodipine once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aliskiren</title>
          <description>Aliskiren 150-300 mg once daily</description>
        </group>
        <group group_id="B2">
          <title>Amlodipine</title>
          <description>5-10 mg amlodipine once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" spread="10"/>
                    <measurement group_id="B2" value="63" spread="16"/>
                    <measurement group_id="B3" value="65" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasminogen Activator Inhibitor 1</title>
        <description>Plasminogen Activator Inhibitor 1 is a biomarker found in serum that indirectly assesses blood clotting activity. Lower PAI-1 levels are thought to be better than higher levels. The primary outcome is mean change from baseline and can include negative numbers as a result.</description>
        <time_frame>6 weeks (change from baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 150-300 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine</title>
            <description>5-10 mg amlodipine once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Plasminogen Activator Inhibitor 1</title>
          <description>Plasminogen Activator Inhibitor 1 is a biomarker found in serum that indirectly assesses blood clotting activity. Lower PAI-1 levels are thought to be better than higher levels. The primary outcome is mean change from baseline and can include negative numbers as a result.</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" lower_limit="-7.33" upper_limit="8.62"/>
                    <measurement group_id="O2" value="3.82" lower_limit="-5.16" upper_limit="12.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Level of Vascular Cell Adhesion Molecule</title>
        <description>Surrogate biomarker cardiovascular risk</description>
        <time_frame>6 week (change from baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 150-300 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine</title>
            <description>5-10 mg amlodipine once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Level of Vascular Cell Adhesion Molecule</title>
          <description>Surrogate biomarker cardiovascular risk</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" lower_limit="-41.1" upper_limit="36.3"/>
                    <measurement group_id="O2" value="-45.9" lower_limit="-112.8" upper_limit="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Level of Intracellular Cell Adhesion Molecule</title>
        <description>Surrogate biomarker of cardiovascular risk</description>
        <time_frame>6 week (change from baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 150-300 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine</title>
            <description>5-10 mg amlodipine once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Level of Intracellular Cell Adhesion Molecule</title>
          <description>Surrogate biomarker of cardiovascular risk</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" lower_limit="-17.2" upper_limit="7.4"/>
                    <measurement group_id="O2" value="-10.3" lower_limit="-31.2" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Level of C-reactive Protein</title>
        <description>Surrogate biomarker of cardiovascular risk</description>
        <time_frame>6 week (change from baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 150-300 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine</title>
            <description>5-10 mg amlodipine once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Level of C-reactive Protein</title>
          <description>Surrogate biomarker of cardiovascular risk</description>
          <units>mg/l</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0397" lower_limit="-0.2310" upper_limit="0.3104"/>
                    <measurement group_id="O2" value="0.1032" lower_limit="-0.1974" upper_limit="0.4038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Level of Nitric Oxide</title>
        <description>Surrogate biomarker of cardiovascular risk</description>
        <time_frame>6 week (change from baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 150-300 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine</title>
            <description>5-10 mg amlodipine once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Level of Nitric Oxide</title>
          <description>Surrogate biomarker of cardiovascular risk</description>
          <units>mmmol/l</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" lower_limit="-7.45" upper_limit="12.76"/>
                    <measurement group_id="O2" value="7.49" lower_limit="-1.43" upper_limit="16.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aliskiren</title>
          <description>Aliskiren 150-300 mg once daily</description>
        </group>
        <group group_id="E2">
          <title>Amlodipine</title>
          <description>5-10 mg amlodipine once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size led to large standard deviation in biomarkers assessed and limited power to detect a diffference</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gary Meyerrose</name_or_title>
      <organization>Texas Tech University Health Sciences Center School of Medicine</organization>
      <phone>806-743-3150</phone>
      <email>gary.meyerrose@ttuhsc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

